Azacitidine 150 Mg Accord 150 mg Powder for suspension for injection)
PDF Leaflet Revision Date: 11 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelodysplastic syndromes.
Dosage (summary)
75 mg/mu00b2 subcutaneously daily for 7 days every 4 weeks; may increase to 100 mg/mu00b2.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not known if excreted in breast milk.
Contraindications
- Hypersensitivity to azacitidine
- Advanced malignant hepatic tumours
- Severe renal impairment
- Pregnancy
- Children under 18
Common side effects
- Anaemia
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
Counselling Points
- Monitor for signs of bleeding
- Report febrile episodes
- Use effective contraception during treatment
Serious warnings
- Haematological toxicity
- Risk of necrotising fasciitis
- Potential for renal failure
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
